Interview with Israel Garcia Crespo, General Manager, Almirall Mexico
Please can you give us a brief rundown of the last few years in the Mexican pharmaceutical and how the various regulation changes such as the new drug registration process…
Address: Periferico Sur 3325 Piso 1, Col. San Jeronimo Lidice, Mexico D.F.
,Mexico
Tel: +52 5 559 998 600
Web: http://www.almirall.com/webcorp2/cda/index.jsp
Almirall is an international pharmaceutical company with headquarters in Spain, based on innovation and committed to health, and develops, manufactures and commercializes its own Research & Development driven licensed drugs, with the aim of improving health and welfare of people. Currently, our drugs are marketed in over 70 countries including the USA and Japan, either through our own subsidiaries or through marketing agreements with renowned pharmaceutical companies. Almirall has 11 subsidiaries in Europe, including Spain, Germany, Austria, Belgium, France, Italy, Poland, Portugal, United Kingdom, Ireland and Switzerland and Mexico. Almirall S.A. de C.V.- the company’s only Latin American presence- began operating in 2000 with the aim of consolidating the company’s international expansion and entering placing its main strategic products into the Mexican market specifically.
Almirall S.A. de C.V. currently has 9 innovative products in the Mexican market in fields ranging from Dermatology to Oncology, which provide solutions to Mexican society in improving their quality of life and health.
Please can you give us a brief rundown of the last few years in the Mexican pharmaceutical and how the various regulation changes such as the new drug registration process…
Two companies from two different countries chose Mexico as their entry market to Latin America. The heads of these companies spoke to PharmaBoardroom about their market entry strategies. Edmée Stenken,…
The industry of medical devices is soaring in Mexico. The general manager of ConvaTec discusses strategic priorities, new approaches and how reduced time to market is feeding the double-digit growth…
IMS Health recently released its World Review 2015. The new general manager of North Latin America shares the company’s assessment on the performance of the Mexican pharmaceutical market for 2014,…
The industry of medical devices is still not very well understood. Pablo Dávila shared with us his overview on the Mexican market, how the Mexican Association of Innovative Medical Device…
The technical & RA director and the managing director of Qually Corporacion explain how authorized third partied act as an extension of the regulative body, Cofepris, helping to assure that…
The managing director of MSD in Mexico explains why the Mexican pharmaceutical market is an attractive market in which to compete, but not one that will deliver 12 to 15…
Claudio Soto, general manager of PAREXEL Mexico, discusses how the clinical research process required to receive approval for a new clinical protocol in Mexico is fairly straightforward compared to other…
The pharmaceutical and medical devices industries are both classified as emerging sectors by the Ministry of Economy. The undersecretary of industry and commerce discusses the importance of the sectors to…
In public health everything is a priority. The Undersecretary of Prevention and Health Promotion explains how Mexico’s Ministry of Health is handling the country’s changing epidemiological profile without forgetting communicable…
The implementation of third authorized parties has been a very proactive effort implemented by Mexico’s regulatory authority Cofepris to expedite the time to issue sanitary registrations. The CEO of Entimem…
Starting a new business is no easy task. The general manager of Alliance SFA shares his experience, how he decided to focus on second-tier and niche players to offer tailor-made…
Founded back in 1956, Laboratorios Keton is a small 100 percent Mexican company committed to provide high-quality contract manufacturing services to local as well as international drug makers. With more…
See our Cookie Privacy Policy Here
